The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Coagulation Factor VIIa Market Research Report 2024
Synopsis
Recombinant activated factor VII (rFVIIa) binds to exposed tissue factor at the place of tissue and vascular injury. Thrombin generated by this process activates platelets and the coagulation cascade.
The global Coagulation Factor VIIa market was valued at US$ 1179.9 million in 2023 and is anticipated to reach US$ 1529.8 million by 2030, witnessing a CAGR of 3.7% during the forecast period 2024-2030.
Due to the COVID-19 pandemic, the global Recombinant Human Coagulation VIIa market size is estimated to be worth US$ 1180 million in 2022 and is forecast to a readjusted size of US$ 1467 million by 2028 with a CAGR of 3.7% during the forecast period 2022-2028. Market driver is mainly rising number of hemophilia patients across the world. Recombinant coagulation factors, as opposed to plasma-derived counterparts, consume a very low risk for transfer of infectious diseases and their use would eliminate the risk of infection from viruses such as the human immunodeficiency virus and hepatitis C. The advancement of recombinant coagulation factors has been a major importance in hemophilia care promising nearly complete safety of individuals from the risk of transmitted infections.
This report aims to provide a comprehensive presentation of the global market for Coagulation Factor VIIa, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Coagulation Factor VIIa.
Report Scope
The Coagulation Factor VIIa market size, estimations, and forecasts are provided in terms of sales volume (MT) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Coagulation Factor VIIa market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Coagulation Factor VIIa manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novo Nordisk
LFB SA HEMA Biologics
AryoGen Pharmed
GENERIUM
Segment by Type
Prefilled Syringe
Vial
Segment by Application
Congenital Hemophilia
Acquired Hemophilia
Other
Consumption by Region
North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Coagulation Factor VIIa manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Coagulation Factor VIIa in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Recombinant activated factor VII (rFVIIa) binds to exposed tissue factor at the place of tissue and vascular injury. Thrombin generated by this process activates platelets and the coagulation cascade.
The global Coagulation Factor VIIa market was valued at US$ 1179.9 million in 2023 and is anticipated to reach US$ 1529.8 million by 2030, witnessing a CAGR of 3.7% during the forecast period 2024-2030.
Due to the COVID-19 pandemic, the global Recombinant Human Coagulation VIIa market size is estimated to be worth US$ 1180 million in 2022 and is forecast to a readjusted size of US$ 1467 million by 2028 with a CAGR of 3.7% during the forecast period 2022-2028. Market driver is mainly rising number of hemophilia patients across the world. Recombinant coagulation factors, as opposed to plasma-derived counterparts, consume a very low risk for transfer of infectious diseases and their use would eliminate the risk of infection from viruses such as the human immunodeficiency virus and hepatitis C. The advancement of recombinant coagulation factors has been a major importance in hemophilia care promising nearly complete safety of individuals from the risk of transmitted infections.
This report aims to provide a comprehensive presentation of the global market for Coagulation Factor VIIa, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Coagulation Factor VIIa.
Report Scope
The Coagulation Factor VIIa market size, estimations, and forecasts are provided in terms of sales volume (MT) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Coagulation Factor VIIa market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Coagulation Factor VIIa manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novo Nordisk
LFB SA HEMA Biologics
AryoGen Pharmed
GENERIUM
Segment by Type
Prefilled Syringe
Vial
Segment by Application
Congenital Hemophilia
Acquired Hemophilia
Other
Consumption by Region
North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Coagulation Factor VIIa manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Coagulation Factor VIIa in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Coagulation Factor VIIa Market Overview
1.1 Product Overview and Scope of Coagulation Factor VIIa
1.2 Coagulation Factor VIIa Segment by Type
1.2.1 Global Coagulation Factor VIIa Market Value Comparison by Type (2024-2030)
1.2.2 Prefilled Syringe
1.2.3 Vial
1.3 Coagulation Factor VIIa Segment by Application
1.3.1 Global Coagulation Factor VIIa Market Value by Application: (2024-2030)
1.3.2 Congenital Hemophilia
1.3.3 Acquired Hemophilia
1.3.4 Other
1.4 Global Coagulation Factor VIIa Market Size Estimates and Forecasts
1.4.1 Global Coagulation Factor VIIa Revenue 2019-2030
1.4.2 Global Coagulation Factor VIIa Sales 2019-2030
1.4.3 Global Coagulation Factor VIIa Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Coagulation Factor VIIa Market Competition by Manufacturers
2.1 Global Coagulation Factor VIIa Sales Market Share by Manufacturers (2019-2024)
2.2 Global Coagulation Factor VIIa Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Coagulation Factor VIIa Average Price by Manufacturers (2019-2024)
2.4 Global Coagulation Factor VIIa Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Coagulation Factor VIIa, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Coagulation Factor VIIa, Product Type & Application
2.7 Coagulation Factor VIIa Market Competitive Situation and Trends
2.7.1 Coagulation Factor VIIa Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Coagulation Factor VIIa Players Market Share by Revenue
2.7.3 Global Coagulation Factor VIIa Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Coagulation Factor VIIa Retrospective Market Scenario by Region
3.1 Global Coagulation Factor VIIa Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Coagulation Factor VIIa Global Coagulation Factor VIIa Sales by Region: 2019-2030
3.2.1 Global Coagulation Factor VIIa Sales by Region: 2019-2024
3.2.2 Global Coagulation Factor VIIa Sales by Region: 2025-2030
3.3 Global Coagulation Factor VIIa Global Coagulation Factor VIIa Revenue by Region: 2019-2030
3.3.1 Global Coagulation Factor VIIa Revenue by Region: 2019-2024
3.3.2 Global Coagulation Factor VIIa Revenue by Region: 2025-2030
3.4 North America Coagulation Factor VIIa Market Facts & Figures by Country
3.4.1 North America Coagulation Factor VIIa Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Coagulation Factor VIIa Sales by Country (2019-2030)
3.4.3 North America Coagulation Factor VIIa Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.4.6 Mexico
3.5 Europe Coagulation Factor VIIa Market Facts & Figures by Country
3.5.1 Europe Coagulation Factor VIIa Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Coagulation Factor VIIa Sales by Country (2019-2030)
3.5.3 Europe Coagulation Factor VIIa Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 UK
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Coagulation Factor VIIa Market Facts & Figures by Country
3.6.1 Asia Pacific Coagulation Factor VIIa Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Coagulation Factor VIIa Sales by Country (2019-2030)
3.6.3 Asia Pacific Coagulation Factor VIIa Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Coagulation Factor VIIa Market Facts & Figures by Country
3.7.1 Latin America Coagulation Factor VIIa Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Coagulation Factor VIIa Sales by Country (2019-2030)
3.7.3 Latin America Coagulation Factor VIIa Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Coagulation Factor VIIa Market Facts & Figures by Country
3.8.1 Middle East and Africa Coagulation Factor VIIa Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Coagulation Factor VIIa Sales by Country (2019-2030)
3.8.3 Middle East and Africa Coagulation Factor VIIa Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Coagulation Factor VIIa Sales by Type (2019-2030)
4.1.1 Global Coagulation Factor VIIa Sales by Type (2019-2024)
4.1.2 Global Coagulation Factor VIIa Sales by Type (2025-2030)
4.1.3 Global Coagulation Factor VIIa Sales Market Share by Type (2019-2030)
4.2 Global Coagulation Factor VIIa Revenue by Type (2019-2030)
4.2.1 Global Coagulation Factor VIIa Revenue by Type (2019-2024)
4.2.2 Global Coagulation Factor VIIa Revenue by Type (2025-2030)
4.2.3 Global Coagulation Factor VIIa Revenue Market Share by Type (2019-2030)
4.3 Global Coagulation Factor VIIa Price by Type (2019-2030)
5 Segment by Application
5.1 Global Coagulation Factor VIIa Sales by Application (2019-2030)
5.1.1 Global Coagulation Factor VIIa Sales by Application (2019-2024)
5.1.2 Global Coagulation Factor VIIa Sales by Application (2025-2030)
5.1.3 Global Coagulation Factor VIIa Sales Market Share by Application (2019-2030)
5.2 Global Coagulation Factor VIIa Revenue by Application (2019-2030)
5.2.1 Global Coagulation Factor VIIa Revenue by Application (2019-2024)
5.2.2 Global Coagulation Factor VIIa Revenue by Application (2025-2030)
5.2.3 Global Coagulation Factor VIIa Revenue Market Share by Application (2019-2030)
5.3 Global Coagulation Factor VIIa Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Novo Nordisk
6.1.1 Novo Nordisk Corporation Information
6.1.2 Novo Nordisk Description and Business Overview
6.1.3 Novo Nordisk Coagulation Factor VIIa Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Novo Nordisk Coagulation Factor VIIa Product Portfolio
6.1.5 Novo Nordisk Recent Developments/Updates
6.2 LFB SA HEMA Biologics
6.2.1 LFB SA HEMA Biologics Corporation Information
6.2.2 LFB SA HEMA Biologics Description and Business Overview
6.2.3 LFB SA HEMA Biologics Coagulation Factor VIIa Sales, Revenue and Gross Margin (2019-2024)
6.2.4 LFB SA HEMA Biologics Coagulation Factor VIIa Product Portfolio
6.2.5 LFB SA HEMA Biologics Recent Developments/Updates
6.3 AryoGen Pharmed
6.3.1 AryoGen Pharmed Corporation Information
6.3.2 AryoGen Pharmed Description and Business Overview
6.3.3 AryoGen Pharmed Coagulation Factor VIIa Sales, Revenue and Gross Margin (2019-2024)
6.3.4 AryoGen Pharmed Coagulation Factor VIIa Product Portfolio
6.3.5 AryoGen Pharmed Recent Developments/Updates
6.4 GENERIUM
6.4.1 GENERIUM Corporation Information
6.4.2 GENERIUM Description and Business Overview
6.4.3 GENERIUM Coagulation Factor VIIa Sales, Revenue and Gross Margin (2019-2024)
6.4.4 GENERIUM Coagulation Factor VIIa Product Portfolio
6.4.5 GENERIUM Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Coagulation Factor VIIa Industry Chain Analysis
7.2 Coagulation Factor VIIa Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Coagulation Factor VIIa Production Mode & Process
7.4 Coagulation Factor VIIa Sales and Marketing
7.4.1 Coagulation Factor VIIa Sales Channels
7.4.2 Coagulation Factor VIIa Distributors
7.5 Coagulation Factor VIIa Customers
8 Coagulation Factor VIIa Market Dynamics
8.1 Coagulation Factor VIIa Industry Trends
8.2 Coagulation Factor VIIa Market Drivers
8.3 Coagulation Factor VIIa Market Challenges
8.4 Coagulation Factor VIIa Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
